Point72 Asset Management L.P. Acquires New Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Point72 Asset Management L.P. purchased a new stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 1,627,590 shares of the company's stock, valued at approximately $11,295,000. Point72 Asset Management L.P. owned about 0.43% of GoodRx at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cornercap Investment Counsel Inc. boosted its position in shares of GoodRx by 1.7% during the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company's stock worth $587,000 after purchasing an additional 1,266 shares in the last quarter. California State Teachers Retirement System boosted its stake in GoodRx by 5.1% during the 1st quarter. California State Teachers Retirement System now owns 70,912 shares of the company's stock valued at $503,000 after purchasing an additional 3,444 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of GoodRx in the third quarter worth approximately $33,000. Plato Investment Management Ltd purchased a new stake in shares of GoodRx in the second quarter worth approximately $43,000. Finally, XTX Topco Ltd lifted its holdings in shares of GoodRx by 42.4% in the second quarter. XTX Topco Ltd now owns 29,560 shares of the company's stock valued at $231,000 after purchasing an additional 8,801 shares in the last quarter. 63.77% of the stock is currently owned by institutional investors.

GoodRx Stock Performance

NASDAQ:GDRX traded up $0.01 during trading hours on Friday, reaching $4.91. The company had a trading volume of 922,616 shares, compared to its average volume of 2,164,503. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -163.67, a PEG ratio of 3.69 and a beta of 1.29. GoodRx Holdings, Inc. has a 52 week low of $4.09 and a 52 week high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm's 50 day moving average price is $5.80 and its 200-day moving average price is $7.16.

Wall Street Analyst Weigh In

GDRX has been the subject of several recent analyst reports. Citigroup reduced their target price on shares of GoodRx from $10.00 to $7.00 and set a "buy" rating for the company in a research note on Wednesday, November 13th. Mizuho initiated coverage on shares of GoodRx in a research note on Wednesday. They issued a "neutral" rating and a $5.00 target price on the stock. Royal Bank of Canada restated an "outperform" rating and set a $10.00 price target on shares of GoodRx in a research note on Friday, August 16th. Finally, Barclays cut their target price on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $8.60.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.